Tuesday, February 27, 2024
Larkspur Biosciences is pioneering a new wave of cancer therapy by developing medicines that target immune evasion where it starts – in the cancer. Our integrated discovery and translational approach identifies cancer-intrinsic factors that drive immune escape. Coupling new mechanistic understanding with chemistry that has unlocked well-validated but previously intractable targets, Larkspur is on track to enter the clinic this year. Larkspur’s lead program is a first-in-class lipid remodeler which exposes cancer cells to the immune system. We delivered the development candidate in 15 months and are rapidly progressing into IND-enabling studies. Our first-in-class Pin1 inhibitors in lead optimization induce anti-tumor activity in both cancer cells and fibroblasts. Larkspur’s machine-learning derived platform LarkX identifies cancer cell-intrinsic drivers of immune evasion for patient selection and target discovery.
CEO/Top Company Official
Lead Product in Development
Targeted protein degrader targeting an undisclosed first-in-class lipid kinase that drives cancer-immune evasion
Development Phase of Primary Product